


**Product Name** : Aficamten  
**Cat. No.** : PC-38077  
**CAS No.** : 2364554-48-1  
**Molecular Formula** : C<sub>18</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>  
**Molecular Weight** : 337.38  
**Target** : Myosin  
**Solubility** : 10 mM in DMSO



### Biological Activity

Aficamten (CK-3773274, CK-274) is a novel next-generation cardiac **myosin** inhibitor (IC<sub>50</sub> =1.4 uM) for treatment of hypertrophic cardiomyopathy.

Aficamten (CK-274) provides a projected human half-life appropriate for once a day dosing, reaching steady state within two weeks, has no substantial CYP induction or inhibition in preclinical assessment and demonstrates a wide therapeutic window in vivo with a clear PK/PD relationship.

### References

Chuang C, et al. *J Med Chem*. 2021 Oct 14;64(19):14142-14152.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com